New combo targets advanced prostate cancer in phase 2 trial
NCT ID NCT04734730
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug talazoparib to standard hormone therapy can better control advanced prostate cancer that still responds to hormone treatment. About 70 men with cancer that has spread will receive the combination. The goal is to see if this approach lowers PSA levels more effectively and shrinks tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-SENSITIVE PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug tame metastatic prostate cancer? a phase 1 trial aims to find out
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a three-drug cocktail outsmart resistant prostate cancer?
- Precision radiation may tame rising PSA after prostate surgery
- New prostate cancer drug HRS-7525 enters first human tests
- Blood test could tell doctors when to stop prostate cancer treatment early